

Article type : Supplement Article

**HARMONIZATION IN PRECLINICAL EPILEPSY RESEARCH:
A JOINT AES/ILAE TRANSLATIONAL INITIATIVE**

Aristea S. Galanopoulou¹, Jacqueline A. French², Terence O'Brien³, and Michele Simonato⁴

¹ Saul R. Korey Department of Neurology, Dominick P. Purpura Department of Neuroscience, Laboratory of Developmental Epilepsy, Montefiore Medical Center, Bronx NY, USA

² New York University Langone Medical Center, Comprehensive Epilepsy Center, New York, NY USA

³ Departments of Medicine and Neurology, The Royal Melbourne Hospital, The University of Melbourne, Parkville, Victoria, Australia

⁴ Section of Pharmacology, Department of Medical Sciences and National Institute of Neuroscience, University of Ferrara, Ferrara, Italy; Division of Neuroscience, University Vita-Salute San Raffaele, Milan, Italy

Running Title: Harmonization in epilepsy research

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/epi.13921](https://doi.org/10.1111/epi.13921)

This article is protected by copyright. All rights reserved

Corresponding author: Aristeia S. Galanopoulou MD PhD
Albert Einstein College of Medicine,
Saul R. Korey Department of Neurology
Dominick P. Purpura Department of Neuroscience
1410 Pelham Parkway South,
Kennedy Center Rm 306
Bronx NY, USA 10461
Tel: +1-718-430-3791
Fax: +1-718-430-8899
E-mail: aristeia.galanopoulou@einstein.yu.edu

Keywords: preclinical research, EEG, common data elements, epilepsy, systematic review, rodent

ABSTRACT:

Among the priority next steps outlined during the first translational epilepsy research workshop in London, UK (2012), jointly organized by the American Epilepsy Society (AES) and the International League Against Epilepsy (ILAE), are the harmonization of research practices used in preclinical studies and the development of infrastructure that facilitates multicenter preclinical studies. The AES/ILAE Translational Task Force of the ILAE has been pursuing initiatives that advance these goals. In this supplement, we present the first reports of the working groups of the Task Force that aim to improve practices of performing rodent video EEG studies in experimental controls, generate systematic reviews of preclinical research data, and develop preclinical common data elements (CDEs) for epilepsy research in animals.

Following the first international translational workshop on optimizing preclinical epilepsy in London (2012), jointly organized by the American Epilepsy Society (AES) and the International League Against Epilepsy (ILAE),¹ a number of priority steps were recognized as important to undertake. Among these, the importance of defining and harmonizing best research practices and building an infrastructure to facilitate data comparisons and sharing for animal studies were thought an important step to accelerate and optimize preclinical epilepsy research. To implement these efforts, the AES and ILAE appointed the AES/ILAE Translational Task Force (TF), co-chaired by Jacqueline French (AES), Aristeia Galanopoulou (AES), Terence O'Brien (ILAE) and Michele Simonato (ILAE). The members of the TF were also jointly appointed by the AES (Amy Brooks-Kayal, Frances Jensen, Helen Scharfman) and ILAE (Marco De Curtis, Akio Ikeda, Asla Pitkänen), while Solomon (Nico) Moshé acted as liaison to the executive committee of the ILAE. The first tasks agreed upon, were the harmonization of rodent video-electroencephalography (vEEG) and electrophysiological studies in rodents (TASK1, co-led by Drs Galanopoulou, De Curtis, and Ikeda), systematic reviews of animal model data (TASK2, co-led by Drs Simonato, Brooks-Kayal, Jensen), creation of preclinical common data elements for epilepsy research (TASK3, co-led by Drs Scharfman, French, Pitkänen), and development of infrastructure for multi-center preclinical studies (TASK4, co-led by Drs O'Brien, Ikeda, and Moshé). Following an open call for volunteers, each TASK formed working groups (WG). The first reports of their work appear in this supplement.

The TASK1-WGs address the technological, methodological aspects and interpretation of electrophysiological studies, done in experimental controls. Unlike human EEGs, where there is a standardized way of performing EEG studies and their interpretation follows widely accepted standards and norms, EEG studies in rodents are done using different types and placements of electrodes, different acquisition and analysis methods and their interpretation varies across labs and investigators. In exploratory studies, the diversity in methods and definitions are often dictated by the experimental goals of each study. However, in preclinical studies aiming to ultimately deliver a new treatment, diagnostic tool, or biomarker to the clinics, the harmonization of the procedures followed to perform or interpret EEG or in vitro electrophysiological studies is essential to allow across study comparisons and cross-validation,

minimize the failures to replicate, and effectively translate the findings into humans, when tested in the clinics. Currently, there is no organized method of determining a normal background in rodent EEG studies, no uniform agreement on what is an electrographic seizure, no system of classifying seizures or other EEG and electrophysiological abnormalities in rodents. As a first step, the goal of each of the first TASK1-WGs was to evaluate and propose methodological standards for performing and interpreting electrophysiological studies in rodents used as experimental controls. The description, definition, terminology, and classification of the abnormal patterns will be done in the future. Early discussions among the TASK1-WG members agreed that the term “normal” is difficult to define in rodents, due to the lack of a prior comprehensive evaluation for neurological or other medical disorders, and the fact that they are exposed to invasive surgeries to place EEG electrodes. As a result, these first TF reports utilize the term “controls” to denote that these animals simply have not had exposure to the specific experimental interventions or settings tested in the respective studies, and prompt the investigators to handle and evaluate these controls with the same protocols as the animals allocated into the other experimental groups. In this supplement, the following TASK1 reports are included. The TASK1-WG1 group reports on best practices pertaining studies using surface or epi-/sub-dural EEG in adult rodent controls.² The TASK1-WG3 group addresses the methodologies and interpretation of depth electrophysiological in vivo studies in adult rodent controls,³ while the TASK1-WG4 group focuses on in vitro electrophysiological studies.⁴ The TASK1-WG5 group proposes standards for data acquisition and analysis for the electrophysiological recordings.⁵ Among the future goals of the TF will be to propose an agreement on terminology and classification of abnormal vEEG and electrophysiological patterns and behaviors, similar to the classification systems that exist for humans.

The goal of the TASK2 group is to organize systematic reviews on various topics important for the preclinical epilepsy research studies. This is an effort done through a collaboration with CAMARADES (Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies) (<http://www.dcn.ed.ac.uk/camarades/default.htm>). Electronic citation repositories allow access to large amounts of articles that cannot be examined by a single individual. Moreover, the statistical power of single basic and preclinical studies is often

insufficient to draw solid conclusions. One approach to address these problems (well established in clinical research) is the use of systematic reviews of the literature and meta-analysis of the data. The idea of TASK2 is to apply these techniques to preclinical epilepsy studies. There are of course many topics in pre-clinical epilepsy research, which are worthy of systematic reviews and meta-analysis. The first selected topic was the identification and characterization of outcome measures used in animal models of epilepsy.⁶ This broad analysis is expected to provide evidence to inform attempts to improve the currently available models of chronic epilepsy. Future goals will be to analyze the effects in epilepsy models of FDA- and EMA-approved drugs, using the same approach. The TASK2 report outlines the objectives, search strategy, selection criteria, and methods for the statistical analyses used in this project.

It is widely believed that harmonization of research methodology and reporting will speed the evaluation of translational therapies. Without methodology to allow labs to perform experiments in similar fashion, or indeed without availability of reporting mechanisms to determine whether there were important differences in execution, it is very difficult to accurately interpret results. Following the experience of the clinical common data elements (CDEs) (<https://www.commondataelements.ninds.nih.gov/default.aspx#page=Default>) proposed by the National Institutes of Neurological Disorders and Stroke (NINDS), which have transformed the way clinical trials are being performed and reported, the TASK3 group, in collaboration with the NINDS (Drs Brandy Fureman and Vicky Whittemore), formed several WGs tasked with the creation of preclinical common data elements (CDEs) and case report forms (CRFs) to be used in animal studies. These include core CDEs/CRFs or CDEs/CRFs for assessing behavior, physiological measures and outcomes, vEEG studies, or for performing pharmacological studies in rodents. The TASK3 report⁷ presents an overview of the purpose and utility of these CDEs/CRFs in optimizing data collection and facilitating collaborative studies and data sharing and an introduction to the future detailed reports of the TASK3-WGs which will present these epilepsy CDEs/CRFs.

These first reports present the first steps of the ongoing translational initiatives, with the hope that these will be useful in facilitating the harmonization of preclinical studies in epilepsy research. This will be essential for the successful implementation of large multicenter pre-

clinical trials, which aim to provide higher level pre-clinical evidence to “de-risk” clinical trials, in particular for potential anti-epileptogenic/disease therapies. The authors welcome feedback from the community as it will be essential to finetune and improve the current and future products of our TF.

Acknowledgements:

We are grateful for the support of the ILAE, AES, and NINDS in the initiatives of the AES/ILAE Translational Task Force. The authors have received financial support by the ILAE, AES, and NINDS for the face to face meetings necessary to perform the work outlined in this supplement.

Disclosures of conflicts of interest:

This report was written by experts selected by the International League Against Epilepsy (ILAE) and the American Epilepsy Society (AES) and was approved for publication by the ILAE and the AES. Opinions expressed by the authors, however, do not necessarily represent the policy or position of the ILAE or the AES.

ASG acknowledges grant support by NINDS RO1 NS091170, U54 NS100064, the United States Department of Defense (W81XWH-13-1-0180), the CURE Infantile Spasms Initiative, research funding from the Heffer Family, the Segal Family Foundations and the Abbe Goldstein/Joshua Lurie and Laurie Marsh/ Dan Levitz families. ASG is co-Editor in Chief of *Epilepsia Open* and has received royalties for publications by Elsevier.

JAF receives New York University (NYU) salary support from the Epilepsy Foundation and for consulting work on behalf of the Epilepsy Study Consortium for Acorda, Adamas, Alexza, Anavex, Axcella Health, Biogen, BioPharm Solutions, Cerecor, Concert Pharmaceuticals, Engage, Eisai, Glaxo Smith-Kline, GW Pharma, Marinus, Nestle-Health Science, Neurelis, Novartis, Pfizer, Pfizer-Neusentis, Ovid, Sage, SK Life Sciences, Sunovion, Takeda, UCB Inc., Upsher Smith, Xenon Pharmaceuticals, Zogenix and Zynerba. J. French has also received research grants from Acorda, Alexza, Eisai Medical Research, Lewis County General Hospital (LCGH), Lundbeck, Pfizer,

SK Life Sciences, Sunovion, UCB Inc., Upsher-Smith and Vertex, as well as grants from the Epilepsy Research Foundation, Epilepsy Study Consortium, Epilepsy Therapy Project, and NINDS. She is on the editorial board of Lancet Neurology, Neurology Today and Epileptic disorders. She is scientific officer for the Epilepsy Foundation for which NYU receives salary support. She has received travel reimbursement related to research, advisory meetings, or presentation of results at scientific meetings from the Epilepsy Study Consortium, the Epilepsy Foundation, Eisai, GW Pharma, Marinus, Nestle Life Sciences, Pfizer, Sage, SK life Sciences, Takeda, UCB Inc., Upsher-Smith, Zogenix, Zynerva.

TOB has received research grant from the NINDS (U54 NS100064).

MS has received grants from the European Community [FP7-PEOPLE-2011-IAPP project 285827 (EPIXCHANGE) and FP7-HEALTH project 602102 (EPITARGET)].

We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

References

1. Galanopoulou AS, Simonato M, French JA, et al. Joint AES/ILAE translational workshop to optimize preclinical epilepsy research. *Epilepsia*. 2013;54 Suppl 4:1-2.
2. Kadam SD, D'Ambrosio R, Duveau V, et al. Methodological standards and interpretation of video-EEG in adult control rodents. A TASK1-WG1 report of the AES/ILAE Translational Task Force of the ILAE. *Epilepsia*. 2017:in press.

3. Hernan AE, Schevon CA, Worrell GA, et al. Methodological standards and functional correlates of depth in vivo electrophysiological recordings in control rodents. A TASK1-WG3 report of the AES/ILAE Translational Task Force of the ILAE. *Epilepsia*. 2017:in press.
4. Raimondo JV, Heinemann U, de Curtis M, et al. Methodological standards for in vitro models of epilepsy and epileptic seizures. A TASK1-WG4 report of the AES/ILAE Translational Task Force of the ILAE. *Epilepsia*. 2017:in press.
5. Moyer JT, Gnatkovsky V, Ono T, et al. Standards for data acquisition and software-based analysis of in vivo electroencephalography recordings from animals: A TASK1-WG5 report of the AES/ILAE Translational Task Force of the ILAE. *Epilepsia*. 2017:in press.
6. Simonato M, Iyengar S, Brooks-Kayal A, et al. Identification and characterization of outcome measures reported in animal models of epilepsy. Protocol for a systematic review of the literature. A TASK2 report of the AES/ILAE Translational Task Force of the ILAE. *Epilepsia*. 2017:in press.
7. Harte-Hartgrove LC, French JA, Pitkänen A, et al. Common data elements for preclinical epilepsy research: standards for data collection and reporting. A TASK3 report of the AES/ILAE Translational Task Force of the ILAE. *Epilepsia*. 2017:in press.